Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)

CUSIP: 89532M101

Q2 2026 13F Holders as of 30 Jun 2026

Security type / class
Equity / Common Stock, $0.001 par value per share
Total 13F shares
516
Total 13F value
$9,623
Holder snapshot 5 signals
Share change
-232
SEC-reported price per share
$18.65
Number of holders
1
Value change
-$2,768
Number of sells
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
143,562,667

Security key

89532M101

Report period

Q2 2026

Institutions

1

Top holders

2

TRVI full security history Ownership snapshot Full 13F holder table Previous quarter: Q1 2026 Trevi Therapeutics, Inc. SEC filings Trevi Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
New Enterprise Associates...
Disclosed value leader
New Enterprise Associates...
Comparable rows
15/15
Latest evidence
05 May 2026
13D/G 3/4/5 13F Lead comparable stake: 10% 13D/G row: New Enterprise Associates 16, L.P. Showing 1-6 of 15 holder rows.

Quick read

New Enterprise Associates 16, L.P. leads the comparable SEC ownership view at 10%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens New Enterprise Associates 16, L.P.'s linked filing trail.
Comparable ownership Top 5
New Enterprise Associates 16, L.P. 10%
Frazier Life Sciences Public Fund... 7%
FMR LLC 6.3%
BlackRock, Inc. 5.6%
VIKING GLOBAL INVESTORS LP 4.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
New Enterprise Associates 16, L.P.
13D/G 3/4/5
10%+ Owner
13D/G 3/4/5
10%
$198,827,115
15,074,080 shares
 $0 05 May 2026
Frazier Life Sciences Public Fund, L.P.
13D/G
13D/G
7%
$77,848,392
8,508,021 shares
 -$16,025,200 30 Sep 2025
FMR LLC
13D/G 13F
Company
13D/G 13F
6.3%
$106,022,020
8,038,061 shares
 +$20,286,893 31 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
5.6%
from 13D/G
$122,165,419
10,240,186 shares
 — 31 Mar 2026
VIKING GLOBAL INVESTORS LP
13D/G 13F
Company
13D/G 13F
4.2%
$46,929,206
5,128,875 shares
 -$21,747,894 30 Sep 2025
Rubric Capital Management LP
13F 13D/G
Company
13F 13D/G
2.9%
from 13D/G
$44,288,610
3,712,373 shares
 — 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
1
Shares
516
Rows available
1
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
196
Q2 2026 holders
1
Holder diff
-195
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .